Virginia Bonilla
Optometrist · Merrillville, INNPI 1891038063
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,559, 4.3 times the $366 reported in 2019. Among optometrist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $45.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Alcon$699
- AbbVie$573
- Coopervision Inc.$507
- Dompe US, Inc.$411
- Tarsus Pharmaceuticals, Inc.$385
- plus $2K from 13 others
What the payments were for
- Speaking & faculty fees$1753%
- Food & beverage$5,67893%
- Gifts$391%
- Entertainment$2194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 29 | $1,110 |
| Alcon | 21 | $699 |
| AbbVie(2 entities) | 7 | $573 |
| Coopervision Inc. | 6 | $507 |
| Dompe US, Inc. | 8 | $411 |
| Tarsus Pharmaceuticals, Inc. | 8 | $385 |
| Oyster Point Pharma, Inc. | 9 | $330 |
| Mallinckrodt Hospital Products Inc. | 6 | $282 |
| Sun Pharmaceutical Industries Inc. | 7 | $274 |
| Glaukos Corporation | 2 | $272 |
| Harrow Eye, LLC | 9 | $238 |
| Optos, Inc. | 2 | $219 |
| Amgen(2 entities) | 7 | $168 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $167 |
| Kala Pharmaceuticals, Inc. | 4 | $158 |
| Biotissue Holdings Inc. | 1 | $110 |
| Aerie Pharmaceuticals, Inc. | 1 | $107 |
| Novartis | 4 | $63 |
| Carl Zeiss Meditec AG | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$268
- OCT OPHTHALMOSCOPE$268
- Oxervate$250
- MiSight Contact Lens$175
- NFC-700$134
- CEQUA$125
- INFUSE MULTIFOCAL$125
- DURYSTA$125
- REVIVE$125
- MIEBO$125
- XIIDRA$125
- TYRVAYA$123
- ACTHAR$120
- EYSUVIS$117
- Prokera$110
- AmnioGraft$110
- Rocklatan$107
- Rhopressa$107
- RESTASIS MULTIDOSE$105
- LUMIGAN$101
How this compares
$6,111 in reported general payments places this provider in the 95th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 106 | $143,184 |
| XiidraLifitegrast | 48 | $87,941 |
| CequaCyclosporine | 16 | $21,001 |
| LumiganBimatoprost | 37 | $20,037 |
| VevyeCyclosporine | 20 | $18,836 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $15,657 |
| Cyclosporine | 38 | $12,567 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,189 |
| Loteprednol Etabonate | 12 | $2,066 |
| Prednisolone Acetate | 29 | $697 |
| Latanoprost | 61 | $428 |
| Azelastine Hcl | 39 | $419 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 32 | $281 |
| ErythromycinErythromycin Base | 19 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $573 | $163,221143 claims |
| Bausch & Lomb Americas Inc.Xiidra | $1,110 | $87,94148 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $274 | $21,00116 claims |
| Harrow Eye, LLCVevye | $238 | $18,83620 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $107 | $15,65716 claims |
| AlconSimbrinza | $699 | $2,18911 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $167 | $2,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,318 optometrist providers in Indiana.
Other optometrist in Merrillville
- John CzajaMerrillville$189K
- Damon DierkerIndianapolis$707K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Rhonda RobinsonIndianapolis$205K
- Peter KollbaumBloomington$60K
- Ryan GustusBluffton$48K
- Steve VargoHighland$48K
- Helen TzanetakosMunster$47K
- Nicholas McColleyGreenfield$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.